Access to credible information on schizophrenia patients’ medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers
Authors Shafrin J, May SG, Shrestha A, Ruetsch C, Gerlanc N, Forma F, Hatch A, Lakdawalla DN, Lindenmayer JP
Received 2 March 2017
Accepted for publication 1 May 2017
Published 27 June 2017 Volume 2017:11 Pages 1071—1081
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Lucy Goodman
Peer reviewer comments 2
Editor who approved publication: Dr Johnny Chen
Jason Shafrin,1 Suepattra G May,1 Anshu Shrestha,1 Charles Ruetsch,2 Nicole Gerlanc,2 Felicia Forma,3 Ainslie Hatch,4 Darius N Lakdawalla,1,5 Jean-Pierre Lindenmayer6
1Precision Health Economics, Los Angeles, CA, 2Health Analytics, Columbia, MD, 3Otsuka Pharmaceutical Development & Commercialization, Inc., 4ODH, Inc., Princeton, NJ, 5Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, 6Department of Psychiatry, New York University School of Medicine, New York, NY, USA
Objective: Overestimating patients’ medication adherence diminishes the ability of psychiatric care providers to prescribe the most effective treatment and to identify the root causes of treatment resistance in schizophrenia. This study was conducted to determine how credible patient drug adherence information (PDAI) might change prescribers’ treatment decisions.
Methods: In an online survey containing 8 clinical case vignettes describing patients with schizophrenia, health care practitioners who prescribe antipsychotics to patients with schizophrenia were instructed to choose a preferred treatment recommendation from a set of predefined pharmacologic and non-pharmacologic options. The prescribers were randomly assigned to an experimental or a control group, with only the experimental group receiving PDAI. The primary outcome was the prescribers’ treatment choice for each case. Between-group differences were analyzed using multinomial logistic regression.
Results: A convenience sample (n=219) of prescribers completed the survey. For 3 nonadherent patient vignettes, respondents in the experimental group were more likely to choose a long-acting injectable antipsychotic compared with those in the control group (77.7% experimental vs 25.8% control; P<0.001). For 2 adherent but poorly controlled patient vignettes, prescribers who received PDAI were more likely to increase the antipsychotic dose compared with the control group (49.1% vs 39.1%; P<0.001). For the adherent and well-controlled patient vignette, respondents in both groups made similar treatment recommendations across all choices (P=0.099), but respondents in the experimental arm were more likely to recommend monitoring clinical stability (87.2% experimental vs 75.5% control, reference group).
Conclusion: The results illustrate how credible PDAI can facilitate more appropriate clinical decisions for patients with schizophrenia.
Keywords: adherence, case vignettes, long-acting injectables, schizophrenia, treatment decision
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other article by this author:
The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma
Shafrin J, Sullivan J, Chou JW, Neely MN, Doan JF, Maclean JR
Published Date: 29 November 2017